, Tracking Stock Market Picks
Enter Symbol:
Cellectar Biosciences Inc. (CLRB) [hlAlert]

Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the Company?s lead compound, is in Phase III development for treatment
of lung cancer under a special protocol assessment and fast track. NOV-002 is also in Phase II development for treatment of early-stage breast cancer and chemotherapy-resistant ovarian cancer. NOV-205, Novelos? second compound, is in Phase Ib development for chronic hepatitis C non responders. Both compounds have completed clinical trials in humans and have been approved for use in Russia where they were originally developed.
( Total: 3 Current Stock Recommendations )
Cellectar Biosciences Inc.   (3)
Buy 100%
Related companies

* As of 8/27/2015 12:00 AM
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy